Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 983-988

  Wang, Meng ^a   Liu, Bao Gang ^a   Yang, Zhao Yang ^a   Hong, Xuan ^a   Chen, Gong Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Prognostic marker; Survivin; VEGF A

Indexed keywords

SURVIVIN; VASCULOTROPIN A;

ADULT; AGED; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE;

EID: 84859471497     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.512     Document Type: Review

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Srinivasula SM and Ashwell JD: IAPs: what's in a name? Mol Cell 30: 123-135, 2008.
3. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D: Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 10: 188-193, 2011.
4. Pavlyukov MS, Antipova NV, Balashova MV, Vinogradova TV, Kopantzev EP and Shakhparonov MI: Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem 286: 23296-23307, 2011.
5. Nowak-Markwitz E, Puła B, Szajnik M, Dziegiel P, Piotrowska A, Zabel M and Spaczyński M: Expression of survivin, SDF-1 and CXCR on tumor cells in ovarian cancer. Ginekol Pol 81: 674-677, 2010.
6. Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL and Ha SW: High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis 26: 1019-1023, 2011.
7. Adamkov M, Halasova E, Kajo K, Machalekova K, Vybohova D, Varga I and Rajcany J: Survivin: a promising biomarker in breast carcinoma. Neoplasma 57: 572-577, 2010.
8. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257, 2002.
9. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB and Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622, 2002.
10. Lee CW, Raskett CM, Prudovsky I and Altieri DC: Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 68: 5273-5281, 2008.
11. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR and Altieri DC: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684, 2007.
12. Li F: Survivin study: what is the next wave? J Cell Physiol 197: 8-29, 2003.
13. Altieri DC, Marchisio PC and Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327-1333, 1999.
14. Shu MG, Guo XT, Zhen HN, Han Y, Chen FL, Li LW and Guo SZ: Enhancing skin flap survival by a cell-permeable wild-type survivin. Med Hypotheses 69: 888-891, 2007.
15. Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, Xu N and Xiao Z: High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol 32: 1147-1153, 2011.
16. Trabulo S, Cardoso AM, Santos-Ferreira T, Cardoso AL, Simões S and Pedroso de Lima MC: Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm 8: 1120-1131, 2011.
17. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M and Kim YM: Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 118: 2191-2199, 2011.
18. Takizawa BT, Uchio EM, Cohen JJ, Wheeler MA and Weiss RM: Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest 25: 678-684, 2007.
19. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y and Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107: 746-756, 2006.
20. Malcles MH, Wang HW, Koumi A, Tsai YH, Yu M, Godfrey A and Boshoff C: Characterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNF alpha-mediated cell death. Br J Cancer 96: 1659-1666, 2007.
21. Nassar A, Lawson D, Cotsonis G and Cohen C: Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 16: 113-120, 2008.
22. Ferrara N, Gerber HP and Le Couter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
23. Giatromanolaki A, Sivridis E and Koukourakis MI: Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 29: 408-417, 2006.
24. Kleespies A: Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 87: 95-104, 2004.
25. Yasumitsu A, Tabata C, Tabata R and Hirayama N: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 5: 479-483, 2010.
26. Zhu H, Chen XP, Zhang WG, Luo SF and Zhang BX: Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol 11: 3855-3859, 2005.
27. Zhang HY, Meng X, Du ZX, et al: Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med 9: 207-213, 2009.
28. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ and Duffy MJ: Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17: 597-604, 2006.
29. Beierle EA, Nagaram A, Dai W, Iyengar M and Chen MK: VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res 127: 21-28, 2005.
30. Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H and Sasamata M: YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu6 lung cancer xenograft model. Anticancer Drugs 22: 454-462, 2011.